Marks the Third Year Since the Launch of the First US Biosimilar Market Report INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Co., Ltd. today released its First Quarter 2025 Biosimilar ...

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market Report, marking the eighth edition of the Quarterly ...

While most of its current revenue comes from the contract manufacturing business, Samsung Biologics aims to increase its exposure in the contract development organization business, which provides a ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.